171 related articles for article (PubMed ID: 36265308)
1. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.
Huttunen R; Sainio A; Hjelt A; Haapanen-Saaristo AM; Määttä J; Rummukainen P; Paatero I; Järveläinen H
Biomed Pharmacother; 2022 Dec; 156():113882. PubMed ID: 36265308
[TBL] [Abstract][Full Text] [Related]
2. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
3. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol.
Pawlos A; Broncel M; Woźniak E; Markiewicz Ł; Piastowska-Ciesielska A; Gorzelak-Pabiś P
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770777
[TBL] [Abstract][Full Text] [Related]
5. Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study.
Kuoni S; Steiner R; Saleh L; Lehmann R; Ochsenbein-Kölble N; Simões-Wüst AP
Biomed Pharmacother; 2024 Feb; 171():116177. PubMed ID: 38262151
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
7. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
Matharu K; Chana K; Ferro CJ; Jones AM
Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
[TBL] [Abstract][Full Text] [Related]
8. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
9. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
[TBL] [Abstract][Full Text] [Related]
11. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
12. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
[TBL] [Abstract][Full Text] [Related]
13. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
14. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
[TBL] [Abstract][Full Text] [Related]
15. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.
Behnammanesh G; Durante ZE; Peyton KJ; Martinez-Lemus LA; Brown SM; Bender SB; Durante W
Front Pharmacol; 2019; 10():362. PubMed ID: 31057401
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin and Amputation Risk: Evidence So Far.
Papadokostaki E; Rizos E; Tigas S; Liberopoulos EN
Int J Low Extrem Wounds; 2020 Mar; 19(1):21-26. PubMed ID: 31698973
[TBL] [Abstract][Full Text] [Related]
18. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
19. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
